Sidney Kimmel Cancer Center at Thomas Jefferson University

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative

Phase 1

Completed

Conditions: Hematologic Malignancies

Interventions: Radiation: Total Body Irradiation (TBI)
Biological: Donor Lymphocyte Infusion (DLI)
Drug: Cyclophosphamide (CY)
Drug: Tacrolimus
Drug: Mycophenolate Mofetil (MMF)
Biological: Hematopoietic Stem Cell Transplant (HSCT)

First Posted Date: 2007-01-31

Last Posted Date: 2016-11-29

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 27

Registration Number: NCT00429143

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation

Phase 1

Completed

Conditions: Hematologic Malignancies

Interventions: Drug: L-leucyl-L-leucine Methyl Ester (LLME)
Drug: Fludarabine
Drug: Cytarabine
Drug: Cyclophosphamide
Drug: Tacrolimus
Drug: Mesna
Biological: Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)
Procedure: Hematopoietic stem cell transplantation (HSCT)

First Posted Date: 2007-01-31

Last Posted Date: 2016-11-29

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 14

Registration Number: NCT00429416

Locations: 🇺🇸
Thomas Jefferson University', Philadelphia, Pennsylvania, United States

Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias

Phase 1

Completed

Conditions: Relapsed Acute Leukemia
Refractory Acute Leukemia

Interventions: Drug: Bortezomib 1.3mg/m^2
Drug: Bortezomib with mitoxantrone, etoposide and cytarabine
Drug: Bortezomib 1.0mg/m^2

First Posted Date: 2006-12-12

Last Posted Date: 2018-04-25

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 55

Registration Number: NCT00410423

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease

Phase 2

Completed

Conditions: Graft-versus-Host Disease

Interventions: Drug: Bortezomib

First Posted Date: 2006-12-08

Last Posted Date: 2016-11-29

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 11

Registration Number: NCT00408928

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer

Phase 1

Completed

Conditions: Parotid Gland Cancer
Head and Neck Cancer
Thyroid Gland Cancer
Melanoma
Stage IV Head and Neck Cancer

Interventions: Drug: Cisplatin
Drug: Docetaxel
Drug: Bevacizumab
Drug: Erlotinib
Radiation: Radiotherapy

First Posted Date: 2006-11-30

Last Posted Date: 2016-10-21

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 13

Registration Number: NCT00405405

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Dutasteride Followed By Ultrasound-Guided Biopsy in Finding Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: dutasteride
Other: placebo

First Posted Date: 2006-11-10

Last Posted Date: 2014-01-10

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 450

Registration Number: NCT00398281

Locations: 🇺🇸
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States

Use of Cone Beam Kilovoltage Imaging in Patients Receiving Radiation Therapy for Head and Neck Cancer

Phase 2

Terminated

Conditions: Head and Neck Neoplasms

Interventions: Device: PTV Reduction

First Posted Date: 2006-07-28

Last Posted Date: 2016-11-29

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 30

Registration Number: NCT00358007

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients

Phase 1

Completed

Conditions: Head and Neck Cancer
Cervix Cancer
Central Nervous System Neoplasms
Brain Cancer

Interventions: Drug: Velcade (bortezomib)

First Posted Date: 2006-05-25

Last Posted Date: 2017-05-09

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 54

Registration Number: NCT00329589

Locations: 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States

Alimta, Carboplatin and Radiation Therapy for Non Small Cell Lung Cancer

Phase 1

Completed

Conditions: Inoperable Non Small Cell Lung Cancer

Interventions: Drug: Premetrexed (Alimta)
Drug: Carboplatin

First Posted Date: 2006-05-25

Last Posted Date: 2016-12-02

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 18

Registration Number: NCT00330044

Locations: 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States

Using Intensity Modulated Radiation Therapy (IMRT) for Brain Metastases

Phase 1

Completed

Conditions: Neoplasm Metastasis

Interventions: Radiation: Intensity-Modulated Radiotherapy (IMRT)

First Posted Date: 2006-05-22

Last Posted Date: 2016-10-21

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 10

Registration Number: NCT00328575

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy